First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease

First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease

Drug eluting stents are considered the “gold standard” for the percutaneous treatment of coronary artery disease. Recent publications have suggested that a reasonable alternative, in well selected cases, may be the ABSORBTM bioresorbable vascular scaffold (BVS) stent. © 2016 Wiley Periodicals, Inc....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Catheterization and cardiovascular interventions 2016-11, Vol.88 (6), p.899-901
Hauptverfasser: Rizik, David G., Shah, Maulik G., Burke, Robert F.
Format: Artikel
Sprache:eng
Schlagworte:
Absorbable Implants
Aged
Aged, 80 and over
bioabsorbable devices/polymers
Coronary Angiography
coronary artery disease
Coronary Artery Disease - diagnosis
Coronary Artery Disease - surgery
Coronary Vessels - diagnostic imaging
Coronary Vessels - surgery
Drug Approval
Drug-Eluting Stents
Humans
Male
Middle Aged
Prosthesis Design
stent restenosis
Tissue Scaffolds
United States
United States Food and Drug Administration
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Drug eluting stents are considered the “gold standard” for the percutaneous treatment of coronary artery disease. Recent publications have suggested that a reasonable alternative, in well selected cases, may be the ABSORBTM bioresorbable vascular scaffold (BVS) stent. © 2016 Wiley Periodicals, Inc.
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.26708